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Abstract
Although cognitions have predicted young adults’ human papillomavirus (HPV) vaccine decision-
making, emotion-based theories of healthcare decision-making suggest that anticipatory emotions 
may be more predictive. This study examined whether anticipated regret was associated with 
young adults’ intentions to receive the HPV vaccine above and beyond the effects of commonly 
studied cognitions. Unvaccinated undergraduates (N = 233) completed a survey assessing Health 
Belief Model (HBM) variables (i.e., perceived severity of HPV-related diseases, perceived risk of 
developing these diseases, and perceived benefits of HPV vaccination), anticipatory emotions (i.e., 
anticipated regret if one were unvaccinated and later developed genital warts or HPV-related 
cancer), and HPV vaccine intentions. Anticipated regret was associated with HPV vaccine 
intentions above and beyond the effects of HBM variables among men. Among women, neither 
anticipated regret nor HBM variables showed consistent associations with HPV vaccine intentions. 
Findings suggest that anticipatory emotions should be considered when designing interventions to 
increase HPV vaccination among college men.
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Introduction
Human papillomavirus (HPV) is the most common sexually transmitted infection, with the 
majority of sexually active individuals contracting the virus at some point in their lifetime 
(Centers for Disease Control and Prevention, 2015). The quadrivalent HPV vaccine guards 
against HPV strains linked to genital warts and several cancers including cervical, oral, anal, 
and penile cancers (US Food and Drug Administration, 2011), whereas the bivalent HPV 
vaccine was approved to guard against HPV strains linked to cervical cancer (US Food and 
Drug Administration, 2013). The quadrivalent HPV vaccine, Gardasil, was approved for 
females aged 9–26 in 2006 and males aged 9–26 in 2009 (US Food and Drug 
Administration, 2011). Additionally, in 2009, the bivalent HPV vaccine, Cervarix, was 
approved for females aged 9–25 (US Food and Drug Administration, 2013). Most recently, a 
nonavalent vaccine, Gardasil 9, was approved for females aged 9–26 and males 9–15 in 
2014 (US Food and Drug Administration, 2015). Each vaccine type requires three doses 
over the course of 6 months (Centers for Disease Control and Prevention, 2015).
Compared to other age groups, individuals aged 20–24 are at highest risk for contracting 
HPV (53.8 % prevalence rate) (Satterwhite et al., 2013). More than 32 % of college women 
experience first-time incidence of HPV within the first 2 years of college (Winer et al., 
2003). Women are more likely than men to have some knowledge of HPV and the HPV 
vaccine (Bynum et al., 2011; Reimer et al., 2014) and to have taken steps toward receiving 
the HPV vaccine (Patel et al., 2013). However, HPV vaccine uptake among both males and 
females has remained low (Btoush et al., 2015; Fontenot et al., 2014; Lindley et al., 2013; 
Ratanasiripong, 2015; Reiter et al., 2013; Schmidt & Parsons, 2014) with only 45 % of 
female college students and 26 % of male college students reporting receipt of the HPV 
vaccine (Fontenot et al., 2014; Lindley et al., 2013).
Correlates of HPV vaccine uptake and intentions among college students have been studied 
largely within the framework of the Health Belief Model (HBM) (Donadiki et al., 2014; 
Krawczyk et al., 2012; Mehta et al., 2013). Developed in the 1950s, the HBM has been 
widely used as a conceptual framework to examine and predict individuals’ willingness to 
engage in protective health behaviors (Janz & Becker, 1984). The HBM proposes that 
cognitive variables are central to people’s decision-making regarding their health behaviors 
(Janz & Becker, 1984). Commonly studied cognitive variables include perceived risk of 
developing an illness, perceived benefits of taking action against developing an illness, and 
perceived barriers to taking action (Donadiki et al., 2014; Krawczyk et al., 2012). 
Knowledge of the illness and associated behavior as well as cues to action (e.g., physician 
recommendation, family/friend recommendation, reminder postcard) are also included in the 
HBM (Champion & Skinner, 2008). In addition, self-efficacy, or the belief that one can take 
the steps necessary to complete an action, was added to the HBM in order to more fully 
capture individuals’ willingness to engage in health behaviors (Janz & Becker, 1984).
In prior studies using the HBM, HPV vaccination behaviors and intentions have been 
examined among young men and women separately (Bennett et al., 2012; Donadiki et al., 
2014; Mehta et al., 2013). Consistent with the HBM, greater perceived barriers to HPV 
vaccination and fewer perceived benefits of vaccination have been associated with non-
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receipt of the HPV vaccine among female college students (Donadiki et al., 2014). 
Furthermore, female college students’ intentions to receive the HPV vaccine have been 
associated with perceived risk of developing HPV, perceived benefits of receiving the 
vaccine, and self-efficacy for receiving the vaccine (Bennett et al., 2012). HBM variables 
have also been correlated with men’s intentions to receive the HPV vaccine (Mehta et al., 
2013). Specifically, in a study evaluating an HBM-based intervention to promote HPV 
vaccination in college men, HPV vaccine acceptability was associated with perceived 
severity of HPV, perceived barriers to receiving the vaccine, and self-efficacy for receiving 
the vaccine (Mehta et al., 2013).
The role of emotions, specifically anticipated regret, also has been considered in relation to 
adults’ willingness to receive the HPV vaccine (Gilbert et al., 2011; Reiter et al. 2010a, b). 
For example, anticipated regret if one did not receive the HPV vaccine and subsequently 
developed an HPV infection was associated with willingness to receive the vaccine among 
US men aged 18–59 (Reiter et al. 2010a, b). Additionally, among lesbian and bisexual 
women aged 18–26, anticipated regret if one did not receive the HPV vaccine and 
subsequently contracted HPV was associated with receiving at least 1 dose of the HPV 
vaccine (McRee et al., 2014).
Although both emotions and cognitions have been correlated with HPV vaccine uptake and 
intentions (Bennett et al., 2012; Donadiki et al., 2014; Gilbert et al., 2011; Mehta et al., 
2013; Reiter et al. 2010a, b), prior studies have not examined the theoretical assumption that 
anticipatory emotions, such as anticipated regret, influence HPV vaccine decision-making 
above and beyond the effects of cognitive factors (Schwarz, 2000). Examination of this 
assumption would have implications for the design of interventions to improve vaccine 
uptake. Research on other preventive health behaviors (e.g., physical activity, HIV 
prevention, and smoking cessation as well as flu vaccination) has supported this theoretical 
assumption (Chapman & Coups, 2006; Janssen et al., 2014; Richard et al., 1995; Wang, 
2011; Weinstein et al., 2007). For example, one study of university employees found that 
anticipated regret and worry were stronger predictors of flu vaccination than perceived risk 
and that these emotions mediated the relationship between perceived risk and flu vaccination 
(Chapman & Coups, 2006).
The extent to which cognitive factors (e.g., perceived severity of HPV-related diseases, 
perceived risk of developing these diseases) are associated with anticipatory emotions 
regarding HPV vaccination also requires study, especially in high-risk populations such as 
college students (Satterwhite et al., 2013). Such relationships should be examined by gender, 
as college women have more knowledge of HPV and the HPV vaccine compared to college 
men (Bynum et al., 2011; Reimer et al., 2014), and the vaccine has primarily been marketed 
to women and girls (Gottlieb, 2013). Thus, the current study draws upon the HBM 
(Hochbaum, 1958; Janz & Becker, 1984; Rosenstock, 1960) and emotion-based decision-
making theories (Anderson, 2003) to examine college students’ intentions to receive the 
HPV vaccine by gender. The study aims are: (1) to examine the extent to which commonly 
studied HBM variables (i.e., perceived severity of HPV-related diseases, perceived risk of 
developing these diseases, and perceived benefits of HPV vaccination) are associated with 
anticipated regret if one were unvaccinated and later developed genital warts or an HPV-
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related cancer; and (2) to examine whether anticipated regret is associated with HPV vaccine 
intentions above and beyond the effects of the three HBM variables. Analyses for each aim 
were conducted separately for college men and women.
Methods
Participants and procedure
Undergraduates at a state university in the northeastern United States were recruited through 
a psychology department research participant pool. Students fulfilled course requirements or 
received extra credit for their participation. All participants were fluent in English and 18 
years of age or older.
The university’s institutional review board approved study procedures. Following an 
informed consent process, participants anonymously completed a 15–30 min online survey. 
The survey was completed in groups ranging from 1–16 participants in a campus computer 
lab. Data were collected from March 2011 through April 2012.
Measures
HPV vaccination—Following a description of HPV vaccination, participants first 
indicated whether they had heard of the HPV vaccine prior to study participation (Centers 
for Disease Control and Prevention, 2008). Having heard of the HPV vaccine was coded as 0 
= no and 1 = yes. Those who had heard of the HPV vaccine were asked to indicate whether 
they had received the vaccine (Centers for Disease Control and Prevention, 2008). 
Participants who had not heard of the vaccine and those who had not received the vaccine 
were coded as unvaccinated.
HPV vaccination intention—Unvaccinated participants rated their intention to ask their 
doctor for the HPV vaccine on a 5-point scale ranging from “not at all likely” to “extremely 
likely” (Zimet et al., 2010). This measure has been used to assess HPV vaccination intention 
among women aged 19–26 years old receiving care through a large, nationwide healthcare 
plan (Zimet et al., 2010).
Anticipated regret—Two items assessed anticipated regret if one were unvaccinated and 
later contracted genital warts or an HPV-related cancer (i.e., oral, anal, or penile cancer in 
the case of men or oral, anal, or cervical cancer in the case of women) (Reiter et al. 2010a). 
Items were rated on 4-point scales ranging from “not at all” to “quite a lot” (Reiter et al. 
2010a).
Health Belief Model variables
Perceived severity—Four items assessed beliefs about the perceived severity of HPV-
related diseases (i.e., genital warts, oral cancer, anal cancer, and penile cancer in the case of 
men or genital warts, oral cancer, anal cancer, and cervical cancer in the case of women) 
(Reiter et al. 2010a). For each item, participants indicated how much they believed that the 
disease would affect their lives using a 4-point scale ranging from “not at all” to “quite a lot” 
(Reiter et al. 2010a). Perceived severity of HPV-related cancers was then averaged across the 
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three applicable cancer types separately for men and women. In the current study, 
Cronbach’s alpha for perceived severity of the HPV-related cancers was .90 for men and .87 
for women.
Perceived risk—Four items assessed the perceived likelihood of developing genital warts, 
oral cancer, anal cancer, and penile cancer for men or genital warts, oral cancer, anal cancer, 
and cervical cancer for women (Reiter et al. 2010a). Perceived risk of developing each of the 
diseases was rated on a 5-point scale ranging from “no chance” to “certain I will get” (Reiter 
et al. 2010a). Responses to items assessing perceived risk of developing an HPV-related 
cancer were averaged across the three gender-appropriate cancer types for men and women 
separately. Cronbach’s alpha for the perceived risk of developing HPV-related cancers was .
93 for men and .87 for women in the current study.
Perceived benefits—Perceived benefits of receiving the HPV vaccine were assessed with 
four items (Reiter et al. 2010a). Specifically, participants rated the perceived efficacy of the 
HPV vaccine for preventing each of four HPV-related diseases (i.e., genital warts, oral 
cancer, anal cancer, and penile cancer in the case of men or genital warts, oral cancer, anal 
cancer, and cervical cancer in the case of women) using a 5-point scale ranging from “no 
protection” to “complete protection” (Reiter et al. 2010a). Perceived benefits of receiving the 
HPV vaccine were averaged across the cancer types separately for men and women. In the 
current study, Cronbach’s alpha for perceived efficacy of the vaccine for preventing HPV-
related cancers was .92 for men and .77 for women.
Statistical analyses
Statistical analyses were conducted using SPSS statistical software (SPSS Inc., 2011, 2012, 
versions 20 and 21, Chicago, IL). Only data from students who had not received the HPV 
vaccination were analyzed. Thus, data from 196 women and 28 men who reported receiving 
the HPV vaccine were excluded from analyses. In addition, data from two unvaccinated men 
and five unvaccinated women with a reported age category of “25 years or older” were 
excluded from analyses because their eligibility status for the vaccine was unknown, as the 
vaccine was only approved for individuals up to 26 years of age (US Food and Drug 
Administration, 2011).
Descriptive statistics for study variables and zero-order correlations between variables were 
computed by gender. Regression analyses also were conducted separately for men and 
women, and whether participants had heard of the HPV vaccine prior to study participation 
was included as a covariate. To address aim 1, a hierarchical multiple regression analysis 
was conducted for each disease type (i.e., genital warts or HPV-related cancer) to examine 
the extent to which three HBM variables (i.e., perceived severity, risk, and benefits) were 
associated with anticipated regret. Prior awareness of the HPV vaccine was entered in the 
first step of the equation and the HBM variables were entered in the second step. Then, to 
address aim 2, a hierarchical multiple regression analysis was conducted for each disease 
type (i.e., genital warts or HPV-related cancer) to examine whether anticipated regret was 
associated with HPV vaccine intentions above and beyond the effects of the three HBM 
variables. Prior awareness of the HPV vaccine was entered in the first step of the equation, 
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followed by the HBM variables (i.e., perceived severity, risk, and benefits) in the second step 
and anticipated regret in the third step.
Post-hoc power analyses were conducted using G*Power statistical software (Heinrich-
Heine-Universität Düsseldorf, 2014, version 3.1.9.2, Düsseldorf, Germany). Power ranged 
from 58 to 95 % for the analyses conducted with male participants and from 29 to 99 % for 
the analyses conducted with female participants (Faul, Erdfelder, Buchner, & Lang, 2009).
Results
Sample characteristics
Participants were 233 undergraduates (149 men and 84 women) who had not received the 
HPV vaccine. Demographic characteristics are listed in Table 1. Briefly, most participants 
were 18–19 years old (67 %) and had health insurance (92 %). Participants were primarily 
single (96 %), and the majority had engaged in sexual intercourse at least once (81 %) and 
self-identified as heterosexual (94 %). Participants reported the following racial/ethnic 
backgrounds: White (56 %), Asian (16 %), Hispanic or Latino/a (9 %), Black or African 
American (9 %), and other or more than one race (9 %). Among women, 82 % had heard of 
the HPV vaccine prior to study participation, whereas 66 % of men had heard of the HPV 
vaccine prior to study participation. A total of seven participants (3 % of the total sample) 
reported an HPV diagnosis (6 women, 1 man).
Preliminary analyses
Means, standard deviations, and Pearson’s correlations between study variables are listed for 
men and women in Tables 2 and 3, respectively. Variables that were positively correlated 
with men’s HPV vaccine intentions included perceived benefits with respect to cancer risk 
reduction and anticipated regret if one were unvaccinated and later developed genital warts 
or an HPV-related cancer (see Table 2). Variables that were positively correlated with 
women’s HPV vaccine intentions included perceived risk of developing genital warts or an 
HPV-related cancer, perceived benefits with respect to genital warts and cancer risk 
reduction, and anticipated regret if one were unvaccinated and later developed genital warts 
(see Table 3).
Relations of HBM variables to anticipated regret
First, HBM variables (i.e., perceived severity of HPV-related diseases, perceived risk of 
developing these diseases, and perceived benefits of HPV vaccination) were examined in 
relation to anticipated regret if one were unvaccinated and later developed genital warts or an 
HPV-related cancer. Results of these hierarchical multiple regression analyses are presented 
by gender in Table 4; each set of HBM variables was significantly associated with 
anticipated regret. Among men, the same pattern of results was obtained across disease types 
(i.e., genital warts or HPV-related cancer). Specifically, perceived severity was positively 
associated with anticipated regret, whereas perceived risk and perceived benefits were 
unrelated to this variable. Results for women also did not vary across disease types (i.e., 
genital warts or HPV-related cancer); perceived severity and perceived benefits were 
positively associated with anticipated regret, whereas perceived risk was unrelated to this 
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variable. Across analyses, the control variable (i.e., whether participants had heard of the 
vaccine prior to study participation) was unrelated to anticipated regret among both men and 
women.
Relations of study variables to HPV vaccine intentions
Next, hierarchical regression analyses were used to examine whether anticipated regret was 
associated with HPV vaccine intentions above and beyond the effects of the three HBM 
variables among men. The overall models were significant (see Table 5). With regard to 
genital warts, anticipated regret was positively associated with vaccine intentions when 
controlling for the three HBM variables and prior awareness of the vaccine. None of the 
HBM variables or prior awareness of the vaccine were related to this outcome. With regard 
to HPV-related cancer, anticipated regret was positively associated with vaccine intentions 
when controlling for the three HBM variables and prior awareness of the vaccine. In the 
final model, none of the HBM variables or prior awareness of the HPV vaccine were 
associated with vaccine intentions.
The same hierarchical regression analyses were conducted to examine women’s vaccine 
intentions and, although the overall models were significant, a different pattern of results 
was found (see Table 5). With regard to genital warts, anticipated regret was not significantly 
associated with vaccine intentions when controlling for HBM variables and prior awareness 
of the vaccine, and none of the variables were associated with vaccine intentions in the final 
model. The same pattern of findings was obtained with respect to HPV-related cancer, 
except that perceived benefits of the vaccine were positively associated with vaccine 
intentions in the final model.
Discussion
The current study examined a core assumption of emotion-based theories of healthcare 
decision-making, namely that anticipatory emotions such as regret are associated with 
healthcare intentions above and beyond the effects of health-related cognitions (Schwarz, 
2000). This assumption was examined with respect to HPV vaccine intentions in male and 
female college students, a population at high risk of HPV infection (Satterwhite et al., 2013; 
Winer et al., 2003). Results showed that anticipated regret was associated with HPV vaccine 
intentions above and beyond the effects of cognitive factors central to the HBM (i.e., 
perceived severity of HPV-related diseases, perceived risk of developing these diseases, and 
perceived benefits of HPV vaccination) in college men, but not college women. Neither the 
HBM variables, nor prior awareness of the HPV vaccine, were associated with men’s 
vaccine intentions. Among women, neither anticipated regret nor the three HBM variables 
were consistently associated with HPV vaccine intentions. Prior awareness of the HPV 
vaccine also was not associated with vaccine intentions among women. Taken together, 
findings suggest that, among men, anticipatory emotions may play a more central role in 
decision-making regarding HPV vaccination than cognitions related to vaccination. In prior 
research (Bynum et al., 2011; Reimer et al., 2014), men have reported limited knowledge of 
the vaccine, and only 66 % of men had heard of the vaccine prior to participating in the 
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current study. Thus, for some men, emotional reactions to novel information about the 
vaccine may have led to increased vaccine intentions.
Among women, only perceived benefits with respect to cancer risk reduction showed 
consistent associations with HPV vaccine intentions. These findings are similar to prior 
results with female college students (Bennett et al., 2012; Donadiki et al., 2014) and likely 
reflect the marketing of the HPV vaccine as an intervention to reduce cervical cancer risk. 
Given women’s knowledge of the HPV vaccine, those who are unvaccinated may be 
especially challenging to motivate or may be making their decision based upon unassessed 
factors such as religious beliefs. Among women, perceived severity of HPV-related diseases 
was consistently unrelated to HPV vaccine intentions, as found in prior research (Bennett et 
al., 2012; Donadiki et al., 2014). On average, women perceived HPV-related diseases as 
severe, and, thus, findings may be related to limited variability in these perceptions.
Perceived severity of HPV-related diseases and other cognitive factors were also examined in 
relation to anticipated regret. Among both men and women, greater perceived severity of 
HPV-related diseases was consistently associated with higher levels of anticipated regret. 
Students in this study were informed that HPV causes genital warts and HPV-related cancers 
and that a vaccination to prevent HPV exists; thus, it is not surprising that those perceiving 
these diseases as more severe endorsed higher levels of anticipated regret if they were to 
forgo the vaccine. Additionally, among women, greater perceived benefits of the vaccine 
were associated with higher levels of anticipated regret. The consistency of this finding 
across analyses for women may reflect their knowledge of the vaccine. Our results provide 
initial information on health beliefs related to anticipated regret in college students. Findings 
suggest that, among male and female college students, heightening awareness of the severity 
of HPV-related diseases may result in greater anticipated regret associated with forgoing 
HPV vaccination.
Limitations of the current study and directions for future research should be noted. First, 
although the sample was diverse with respect to ethnicity and gender, participants were 
attending one university in the northeastern U.S. Thus, the extent to which findings 
generalize to college students in other geographical locations requires study. Second, the 
current study did not include certain HBM constructs (e.g., self-efficacy); therefore, further 
research is needed to examine their relation to anticipated regret and HPV vaccine 
intentions. In addition, although participants reported whether they had heard of the HPV 
vaccine, their knowledge of HPV and HPV vaccination was not examined. However, 
participants were provided with a description of the HPV vaccine prior to items assessing 
vaccination status and other study variables. Third, the current study relied on self-report 
measures. However, a recent study suggested a high rate of concordance between self-report 
and electronic medical record data for HPV vaccination among young women (age 18–26) 
with 57.9 % of study participants self-reporting receipt of HPV vaccination and 55.7 % of 
participants receiving the HPV vaccination according to electronic medical record data 
(Rolnick et al., 2013). Fourth, sample sizes may have reduced statistical power for detecting 
effects; post hoc power analyses suggested that three of the eight models were 
underpowered. Finally, longitudinal studies are needed to establish the predictive value of 
cognitive and emotional factors in HPV vaccine intentions and receipt.
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The current findings carry implications for future intervention research to promote HPV 
vaccination in college students. Specifically, results suggest that interventions which only 
address beliefs about the HPV vaccine may not be sufficient for promoting HPV vaccination 
among young men. To date, most HPV vaccine interventions for young adults have focused 
on educating participants about their risk for developing HPV and the availability of the 
HPV vaccine (Gross et al., 2014; Kester et al., 2014). For example, interventions have 
involved listening to professional lectures or receiving fact sheets on HPV vaccination 
(Gross et al., 2014; Kester et al., 2014). The degree to which these interventions have 
increased young adults’ HPV vaccine uptake and intentions has been variable (Gross et al., 
2014; Kester et al., 2014). Furthermore, results of a systematic review of educational 
interventions to promote HPV vaccination in various populations, including young adults, 
suggested that the effects of these interventions on HPV vaccine intentions may be short-
lived (Fu et al., 2014). Thus, education regarding the vaccine may not adequately promote 
uptake.
The present findings also suggest that interventions targeting anticipatory emotions (e.g., 
anticipated regret, worry) should be considered as an alternative to increasing HPV vaccine 
intentions and behaviors among male college students. For example, an ongoing study is 
testing the effect of completing a standardized assessment of anticipated regret on breast 
cancer screening (Chambers et al., 2014); this approach might also be tested with respect to 
HPV vaccination in college men. Another possible approach to targeting anticipated regret 
involves asking male college students to write a reflective paragraph about their anticipated 
regret if they were to forgo the HPV vaccine and were subsequently diagnosed with genital 
warts or an HPV-related cancer. Alternatively, college men could watch a video of an 
unvaccinated individual who subsequently developed an HPV-related disease (Cody & Lee, 
1990). In this video, the person would reflect upon his beliefs when initially offered the 
HPV vaccine and emotions, including regret related to forgoing the vaccine. Although our 
findings suggest that an emotion-based intervention may promote vaccination in men, these 
implications should be made with caution, given the modest associations between men’s 
anticipated regret and vaccine intentions.
In the current study, anticipated regret was associated with HPV vaccine intentions above 
and beyond the effects of several cognitive factors central to the HBM in college men, but 
not college women. Findings of this study and prior research (Bennett et al., 2012; Donadiki 
et al., 2014; Fisher et al., 2013; Gilbert et al., 2011; Loewenstein et al., 2001; Mehta et al., 
2013; Reiter et al. 2010a, b) suggest that future research on HPV vaccine decision-making in 
college students should draw upon emotion-based theories of decision-making (Anderson, 
2003; Schwarz, 2000) in addition to cognitively-based health behavior theories (Hochbaum, 
1958; Janz & Becker, 1984; Rosenstock, 1960). In addition, potential gender differences in 
correlates of HPV vaccination should be considered, especially given the greater awareness 
of the vaccine among women relative to men and previously documented gender differences 
in emotions, cognitions, intentions, and behaviors related to disease prevention (Cody & 
Lee, 1990; Courtenay et al., 2002; McQueen et al., 2008). Understanding factors associated 
with greater HPV vaccine intentions and uptake in college students may lead to more 
efficacious interventions to promote vaccination and ultimately reduce incidence and 
mortality from HPV-related diseases.
Christy et al. Page 9
J Behav Med. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Acknowledgments
The work of the first author was funded initially by R25CA117865 (V. Champion, PI) and subsequently by 
R25CA090314 (P. Jacobsen, PI) from the National Cancer Institute. The work of the second author was funded by a 
fellowship from the Behavioral Cooperative Oncology Group Center for Symptom Management and the Walther 
Cancer Foundation. The work of the last author was funded by K07CA168883 (C. Mosher, PI) and K05CA175048 
(V. Champion, PI) from the National Cancer Institute. The content is solely the responsibility of the authors and 
does not necessarily represent the official views of the National Cancer Institute.
References
Anderson CJ. The psychology of doing nothing: Forms of decision avoidance result from reason and 
emotion. Psychological Bulletin. 2003; 129:139–167. doi:10.1037/0033-2909.129.1.139. [PubMed: 
12555797] 
Bennett KK, Buchanan JA, Adams AD. Social-cognitive predictors of intention to vaccinate against 
the human papillomavirus in college-age women. Journal of Social Psychology. 2012; 152:480–492. 
doi:10.1080/00224545.2011.639408. [PubMed: 22822686] 
Btoush RM, Brown DR, Fogarty S, Carmody DP. Initiation of Human Papillomavirus vaccination 
among predominantly minority female and male adolescents at inner-city community health centers. 
American Journal of Public Health. 2015 doi:10.2105/AJPH.2015.302584. 
Bynum SA, Brandt HM, Friedman DB, Annang L, Tanner A. Knowledge, beliefs, and behaviors: 
Examining human papillomavirus-related gender differences among African American college 
students. Journal of American College Health. 2011; 59:296–302. doi:
10.1080/07448481.2010.503725. [PubMed: 21308590] 
Centers for Disease Control and Prevention. 2008 National Immunization Survey-Teen Hard Copy 
Questionnaire. Centers for Disease Control and Prevention; Hyattsville, MD: 2008. 
Centers for Disease Control and Prevention. Genital HPV infection—Fact sheet. 2015. Retrieved 
September 9, 2015, from http://www.cdc.gov/std/hpv/stdfact-hpv.htm
Chambers JA, O’Carroll RE, Cook A, Cavanagh J, Archibald D, Millar R. A pilot telephone 
intervention to increase uptake of breast cancer screening in socially deprived areas in Scotland 
(TELBRECS): Study protocol for a randomised controlled trial. BMC Public Health. 2014; 14:824. 
doi:10.1186/1471-2458-14-824. [PubMed: 25106506] 
Champion, VL.; Skinner, CS. The Health Belief Model. In: Glanz, K.; Rimer, BK.; Viswanath, K., 
editors. Health behavior and health education: Theory, research and practice. Jossey-Bass/Wiley; 
San Francisco, CA: 2008. p. 45-66.
Chapman GB, Coups EJ. Emotions and preventive health behavior: Worry, regret, and influenza 
vaccination. Health Psychology. 2006; 25:82–90. doi:10.1037/0278-6133.25.1.82. [PubMed: 
16448301] 
Cody R, Lee C. Behaviors, beliefs, and intentions in skin cancer prevention. Journal of Behavioral 
Medicine. 1990; 13:373–389. doi:10.1007/BF00844885. [PubMed: 2246784] 
Courtenay WH, McCreary DR, Merighi JR. Gender and ethnic differences in health beliefs and 
behaviors. Journal of Health Psychology. 2002; 7:219–231. doi:10.1177/1359105302007003216. 
[PubMed: 22114246] 
Donadiki EM, Jiménez-García R, Hernández-Barrera V, Sourtzi P, Carrasco-Garrido P, López de 
Andrés A, Velonakis EG. Health Belief Model applied to non-compliance with HPV vaccine 
among female university students. Public Health. 2014; 128:268–273. doi:10.1016/j.puhe.
2013.12.004. [PubMed: 24529635] 
Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G*Power 3.1: Tests for 
correlation and regression analyses. Behavior Research Methods. 2009; 41:1149–1160. [PubMed: 
19897823] 
Fisher WA, Kohut T, Salisbury CM, Salvadori MI. Understanding human papillomavirus vaccination 
intentions: Comparative utility of the theory of reasoned action and the theory of planned behavior 
in vaccine target age women and men. The Journal of Sexual Medicine. 2013; 10:2455–2464. doi:
10.1111/jsm.12211. [PubMed: 23745833] 
Christy et al. Page 10
J Behav Med. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fontenot HB, Fantasia HC, Charyk A, Sutherland MA. Human papillomavirus (HPV) risk factors, 
vaccination patterns, and vaccine perceptions among a sample of male college students. Journal of 
American College Health. 2014; 62:186–192. doi:10.1080/07448481.2013.872649. [PubMed: 
24328855] 
Fu LY, Bonhomme LA, Cooper SC, Joseph JG, Zimet GD. Educational interventions to increase HPV 
vaccination acceptance: A systematic review. Vaccine. 2014; 32:901–920. doi:10.1016/j.vaccine.
2014.01.091. [PubMed: 24412301] 
Gilbert P, Brewer NT, Reiter PL, Ng TW, Smith JS. HPV vaccine acceptability in heterosexual, gay, 
and bisexual men. American Journal of Men’s Health. 2011; 5:297–305. doi:
10.1177/1557988310372802. 
Gottlieb SD. The patient–consumer–advocate nexus: The marketing and dissemination of Gardasil, the 
Human Papillomavirus Vaccine in the United States. Medical Anthropology Quarterly. 2013; 
27:330–347. doi:10.1111/maq.12046. [PubMed: 24248992] 
Gross MS, Tran CH, Sutherland KH, Castagno JC, Amdur RJ. Pilot study: Can an educational 
intervention increase Human Papillomavirus vaccination in female college students? Obstetrics 
and Gynecology. 2014; 123:1–2. doi:10.1097/01.AOG.0000447062.94587.52. [PubMed: 
24463655] 
Hochbaum, GM. Public participation in medical screening programs: A sociopsychological study. US 
Government Printing Office; Washington, D.C.: 1958. 
Janssen E, Waters EA, van Osch L, Lechner L, de Vries H. The importance of affectively-laden beliefs 
about health risks: The case of tobacco use and sun protection. Journal of Behavioral Medicine. 
2014; 37:11–21. doi:10.1007/s10865-012-9462-9. [PubMed: 23073599] 
Janz NK, Becker MH. The Health Belief Model: A decade later. Health Education & Behavior. 1984; 
11:1–47. doi:10.1177/109019818401100101. 
Kester LM, Shedd-Steele RB, Dotson-Roberts CA, Smith J, Zimet GD. The effects of a brief 
educational intervention on human papillomavirus knowledge and intention to initiate HPV 
vaccination in 18–26 year old young adults. Gynocologic Oncology. 2014; 132:S9–S12. doi:
10.1016/j.ygyno.2013.12.033. 
Krawczyk AL, Perez S, Lau E, Holcroft CA, Amsel R, Knäuper B, Rosberger Z. Human 
papillomavirus vaccination intentions and uptake in college women. Health Psychology. 2012; 
31:685–693. doi:10.1037/a0027012. [PubMed: 22268713] 
Lindley LL, Elkind JS, Landi SN, Brandt HM. Receipt of the human papillomavirus vaccine among 
female college students in the United States, 2009. Journal of American College Health. 2013; 
61:18–27. doi:10.1080/07448481.2012.750607. [PubMed: 23305541] 
Loewenstein GF, Weber EU, Hsee CK, Welch N. Risk as feelings. Psychological Bulletin. 2001; 
127:267–286. doi:10.1037//0033-2909.127.2.267. [PubMed: 11316014] 
McQueen A, Vernon SW, Meissner HI, Rakowski W. Risk perceptions and worry about cancer: Does 
gender make a difference? Journal of Health Communications. 2008; 13:56–79. doi:
10.1080/10810730701807076. 
McRee AL, Katz ML, Paskett ED, Reiter PL. HPV vaccination among lesbian and bisexual women: 
Findings from a national survey of young adults. Vaccine. 2014; 32:4736–4742. doi:10.1016/
j.vaccine.2014.07.001. [PubMed: 25038312] 
Mehta P, Sharma M, Lee RC. Designing and evaluating a Health Belief Model-based intervention to 
increase intent of HPV vaccination among college males. International Quarterly of Community 
Health Education. 2013; 34:101–117. doi:10.2190/IQ.34.1.h. [PubMed: 24366025] 
Patel DA, Grunzweig KA, Zochowski MK, Dempsey AF, Carlos RC, Dalton VK. Human 
papillomavirus vaccine stages of change among male and female university students: Ready or 
not? Journal of American College Health. 2013; 61:336–346. doi:10.1080/07448481.2013.811244. 
[PubMed: 23930748] 
Ratanasiripong NT. Factors related to Human Papillomavirus (HPV) vaccination in college men. 
Public Health Nursing. 2015 doi:10.1111/phn.12198. 
Reimer RA, Schommer JA, Houlihan AE, Gerrard M. Ethnic and gender differences in HPV 
knowledge, awareness, and vaccine acceptability among White and Hispanic men and women. 
Christy et al. Page 11
J Behav Med. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Journal of Community Health. 2014; 39:274–284. doi:10.1007/s10900-013-9773-y. [PubMed: 
24150246] 
Reiter PL, Brewer NT, McRee AL, Gilbert P, Smith JS. Acceptability of HPV vaccine among a 
national sample of gay and bisexual men. Sexually Transmitted Diseases. 2010a; 37:197–203. doi:
10.1097/OLQ.0b013e3181bf542c. [PubMed: 20118831] 
Reiter PL, Brewer NT, Smith JS. Human papillomavirus knowledge and vaccine acceptability among a 
national sample of heterosexual men. Sexually Transmitted Infections. 2010b; 86:241–246. doi:
10.1136/sti.2009.039065. [PubMed: 19951936] 
Reiter PL, Gilkey MB, Brewer NT. HPV vaccination among adolescent males: results from the 
National Immunization Survey-Teen. Vaccine. 2013; 31:2816–2821. doi:10.1016/j.vaccine.
2013.04.010. [PubMed: 23602667] 
Richard R, van der Pligt J, de Vries N. Anticipated affective reactions and prevention of AIDS. British 
Journal of Social Psychology. 1995; 34:9–21. doi:10.1111/j.2044-8309.1995.tb01045.x. [PubMed: 
7735735] 
Rolnick SJ, Parket ED, Nordin JD, Hedblom BD, Wei F, et al. Self-report compared to electronic 
medical record across eight adult vaccines: Do results vary by demographic factors? Vaccine. 
2013; 31:3928–3935. doi:10.1016/j.vaccine.2013.06.041. [PubMed: 23806243] 
Rosenstock IM. What research in motivation suggests for public health. American Journal of Public 
Health and the Nation’s Health. 1960; 50:295–302. doi:10.2105/AJPH.50.3_Pt_1.295. 
Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted 
infections among US women and men: Prevalence and incidence estimates, 2008. Sexually 
Transmitted Diseases. 2013; 40:187–193. doi:10.1097/OLQ.0b013e318286bb53. [PubMed: 
23403598] 
Schmidt S, Parsons HM. Vaccination interest and trends in human papillomavirus vaccine uptake in 
young adult women aged 18 to 26 years in the United States: An analysis using the 2008-2012 
National Health Interview Survey. American Journal of Public Health. 2014; 104:946–953. doi:
10.2105/AJPH.2013.301828. [PubMed: 24625152] 
Schwarz N. Emotion, cognition, and decision making. Cognition and Emotion. 2000; 14:433–440. doi:
10.1080/026999300402745. 
US Food and Drug Administration. Vaccines, blood & biologics: Gardasil. 2011. Retrieved May 6, 
2014, from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/
UCM094042
US Food and Drug Administration. Vaccines, blood & biologics: Cervarix. 2013. Retrieved May 6, 
2014, from http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/
ucm186957.htm
US Food and Drug Administration. Vaccines, blood & biologics: Gardasil 9. 2015. Retrieved August 
24, 2015, from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/
ucm426445.htm
Wang X. The role of anticipated negative emotions and past behavior in individuals’ physical activity 
intentions and behaviors. Psychology of Sport and Exercise. 2011; 12:300–305. doi:10.1016/
j.psychsport.2010.09.007. 
Weinstein ND, Kwitel A, McCaul KD, Magnan RE, Gerrard M, Gibbons FX. Risk perceptions: 
Assessment and relationship to influenza vaccination. Health Psychology. 2007; 26:146–151. doi:
10.1037/0278-6133.26.2.146. [PubMed: 17385965] 
Winer RL, Lee S, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital Human Papillomavirus 
infection: Incidence and risk factors in a cohort of female university students. American Journal of 
Epidemiology. 2003; 157:218–226. doi:10.1093/aje/kwf180. [PubMed: 12543621] 
Zimet GD, Weiss TW, Rosenthal SL, Good MB, Vichnin MD. Reasons for non-vaccination against 
HPV and future vaccination intentions among 19–26 year-old women. BMC Women’s Health. 
2010; 10:27. doi:10.1186/1472-6874-10-27. [PubMed: 20809965] 
Christy et al. Page 12
J Behav Med. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Christy et al. Page 13
Table 1
Sample demographics (N = 233)
Variables N (%)
Age
 18–19 156 (67)
 20–21 66 (28)
 22–24 11 (5)
Gender
 Male 149 (64)
 Female 84 (36)
Race/ethnicity
 White 131 (56)
 Asian/Asian-American 38 (16)
 Hispanic/Latino 21 (9)
 African-American/Black 20 (9)
 Other/More than 1 race 20 (9)
Marital status
 Single 224 (96)
 Living with partner 7 (3)
 Married 1 (<1)
 Separated 1 (<1)
Sexual orientation
 Gay/homosexual 3 (1)
 Bisexual 4 (2)
 Heterosexual 218 (94)
 Other/not sure 8 (3)
Health insurance
 Yes 214 (92)
 No 19 (8)
Heard of HPV vaccine
 Yes 168 (72)
 No 65 (28)
Prior HPV diagnosis
 Yes 7 (3)
 No 224 (96)
Currently in a romantic relationship
 Yes 95 (41)
 No 138 (59)
Have had at least one sexual experience
 Yes 188 (81)
 No 44 (19)
Totals may not add to 100 % due to rounding and/or missing data
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Table 4
Multiple regression analyses of anticipated regret in relation to Health Belief Model variables
Outcome variable Independent variables B R 2 ΔR 2 ΔF p value
Men
 Anticipated regret if unvaccinated and later developed genital warts
  Step 1 <.01 <.01 .13 .72
Have heard of HPV vaccinea .05 .72
  Step 2 .10 .09 4.78 .01
Have heard of HPV vaccinea −.03 .85
Perceived severity of genital warts .24 <.01
Perceived benefits of HPV vaccine against genital warts .12 .10
Perceived risk of genital warts .01 .90
 Anticipated regret if unvaccinated and later developed HPV-related cancer
  Step 1 .01 .01 .94 .34
Have heard of HPV vaccinea .13 .34
  Step 2 .12 .11 5.66 <.01
Have heard of HPV vaccinea .04 .74
Perceived severity of HPV-related cancer .28 <.01
Perceived benefits of HPV vaccine against HPV-related cancer .08 .26
Perceived risk of HPV-related cancer .15 .10
Women
 Anticipated regret if unvaccinated and later developed genital warts
  Step 1 .02 .02 1.97 .17
Have heard of HPV vaccinea .37 .17
  Step 2 .26 .23 8.09 <.01
Have heard of HPV vaccinea .12 .63
Perceived severity of genital warts .40 <.01
Perceived benefits of HPV vaccine against genital warts .23 .02
Perceived risk of genital warts .21 .08
 Anticipated regret if unvaccinated and later developed HPV-related cancer
  Step 1 .02 .02 1.64 .20
Have heard of HPV vaccinea .29 .20
  Step 2 .23 .21 6.77 <.01
Have heard of HPV vaccinea −.21 .40
Perceived severity of HPV-related cancer .58 <.01
Perceived benefits of HPV vaccine against HPV-related cancer .25 .02
Perceived risk of HPV-related cancer −.01 .94
N for men = 143; Ns for women = 80–82; HPV: human papillomavirus. Statistics significant at a p < .05 are denoted in bold. Standardized beta 
coefficients are presented
a
Have heard of HPV vaccine was coded as 0 = no and 1 = yes
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Table 5
Multiple regression analyses of HPV vaccine intention in relation to anticipated regret and Health Belief 
Model variables
Independent variables B R 2 ΔR 2 ΔF p value
Men
 Step 1 .02 .02 2.49 .12
  Have heard of HPV vaccinea −.25 .12
 Step 2 .07 .05 2.43 .048
  Have heard of HPV vaccinea −.24 .14
  Perceived severity of genital warts .06 .51
  Perceived benefits of HPV vaccine against genital warts .16 .07
  Perceived risk of genital warts .20 .07
 Step 3 .10 .03 4.43 .02
  Have heard of HPV vaccinea −.24 .14
  Perceived severity of genital warts .01 .93
  Perceived benefits of HPV vaccine against genital warts .14 .12
  Perceived risk of genital warts .19 .07
  Anticipated regret if unvaccinated and later developed genital warts .22 .04
 Step 1 .02 .02 2.73 .10
  Have heard of HPV vaccinea −.26 .10
 Step 2 .06 .04 2.08 .07
  Have heard of HPV vaccinea −.22 .17
  Perceived severity of HPV-related cancer −.07 .47
  Perceived benefits of HPV vaccine against HPV-related cancer .20 .03
  Perceived risk of HPV-related cancer .10 .38
 Step 3 .12 .05 8.13 .01
  Have heard of HPV vaccinea −.23 .14
  Perceived severity of HPV-related cancer −.15 .13
  Perceived benefits of HPV vaccine against HPV-related cancer .17 .052
  Perceived risk of HPV-related cancer .06 .62
  Anticipated regret if unvaccinated and later developed an HPV-related cancer .29 .01
Women
 Step 1 <.01 <.01 .05 .82
  Have heard of HPV vaccinea .07 .82
 Step 2 .11 .11 3.10 .06
  Have heard of HPV vaccinea .16 .62
  Perceived severity of genital warts .04 .78
  Perceived benefits of HPV vaccine against genital warts .16 .18
  Perceived risk of genital warts .33 .03
 Step 3 .14 .03 2.27 .049
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Independent variables B R 2 ΔR 2 ΔF p value
  Have heard of HPV vaccinea .12 .72
  Perceived severity of genital warts −.05 .74
  Perceived benefits of HPV vaccine against genital warts .11 .37
  Perceived risk of genital warts .28 .06
  Anticipated regret if unvaccinated and later developed genital warts .22 .14
 Step 1 <.01 <.01 .19 .67
  Have heard of HPV vaccinea .14 .67
 Step 2 .20 .20 6.07 <.01
  Have heard of HPV vaccinea .42 .24
  Perceived severity of HPV-related cancer −.18 .42
  Perceived benefits of HPV vaccine against HPV-related cancer .49 <.01
  Perceived risk of HPV-related cancer .25 .15
 Step 3 .22 .02 1.65 <.01
  Have heard of HPV vaccinea .45 .21
  Perceived severity of HPV-related cancer −.30 .21
  Perceived benefits of HPV vaccine against HPV-related cancer .44 .01
  Perceived risk of HPV-related cancer .25 .16
  Anticipated regret if unvaccinated and later developed HPV-related cancer .21 .20
N for men = 142; Ns for women = 78–80; HPV: human papillomavirus. Statistics significant at a p < .05 are denoted in bold. Standardized beta 
coefficients are presented
a
Have heard of HPV vaccine was coded as 0 = no and 1 = yes
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